NYMX
NASDAQ : NYMX

NYMX

June 29, 2005 10:53 ET

Exposure to Mother's Smoke Increases Risk of Asthma in Adults According to New Study; Nymox (NASDAQ:NYMX) TobacAlert™ Product Detects Second-Hand Smoke Exposure

MAYWOOD, N.J.--(CCNMatthews - Jun 29, 2005) -

Childhood exposure to mother's second hand smoke substantially increases the risk for developing adult asthma and other respiratory symptoms according to a new paper published in the current issue of the American Journal of Respiratory and Critical Care Medicine (2005; 172: 61-66).

Nymox Pharmaceutical (NASDAQ:NYMX) makes TobacAlert™, an easy-to-use, cost-effective product that allows for on-site testing for second-hand smoke exposure. TobacAlert™ can be used at home, at school or in the workplace. No instruments are required and results are provided within minutes.

"In our experience, often the biggest surprise comes when the TobacAlert™ test turns out positive for children of smokers who claim to never smoke in the house," according to Brian Doyle, Nymox's Manager of Global Sales and Marketing. "Typically it is then discovered they sometimes smoke in the garage, in the car or in a supposedly isolated room in the home. Sometimes children just can't escape the effects of second-hand smoke."

In the study, researchers surveyed 2,819 adults in Norway about their exposure to second-hand smoke in childhood and about whether their mother smoked during their pregnancy. Exposure to maternal smoking during childhood was found to increase the risk of asthma in adults by 1.9 times; exposure in utero by 2.9 times and the combination of the two factors by 3.5 times.

Nymox's TobacAlert™ product measures the level of cotinine, a metabolite of nicotine, in urine. Cotinine is widely accepted and commonly used in medical research and public health studies to determine the extent of tobacco product use or exposure.

TobacAlert™ is available at over 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information is available at www.tobacalert.com.

The ability of Nymox's tobacco exposure testing technology to measure second-hand smoke exposure has been successfully put to the test by reporters, as reported recently in the New York Daily News and earlier in the London Sunday Telegraph and Melbourne, Australia's The Sunday Herald Sun.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    website: www.nymox.com